Skip to main content

Table 3 Regimens of chemotherapy

From: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

Regimen No. of patients %
Taxane/Cisplatin 191 47.5
Taxane/Cisplatin/5-FU 94 23.4
Irinotecan/5-FU 9 2.2
Oxaliplatin/5-FU 52 12.9
5-FU (oral or infusional fluoropyrimidines)/Cisplatin 21 5.2
Oral fluoropyrimidine 35 8.7
Total 402 100.0